Pharmacologic treatment of male breast cancer

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59(5):995-8
   PubMed Web of Science ®Google Scholar
• El-Gazayerli MM, Abdel-Aziz AS. On Bilharziasis and male breast cancer in Egypt: a preliminary report and review of the literature. Br J Cancer 1963;17:566-71
   PubMed Web of Science ®Google Scholar
• Bhagwandeen SB. Carcinoma of the male breast in Zambia. East Afr Med J 1972;49(2):89-93
   PubMedGoogle Scholar
• Ojara EA. Carcinoma of the male breast in Mulago Hospital, Kampala. East Afr Med J 1978;55(10):489-91
   PubMed Web of Science ®Google Scholar
• Donegan WL, Redlich PN. Breast cancer in men. Surg Clin North Am 1996;76(2):343-63
   PubMed Web of Science ®Google Scholar
• Ravandi-Kashani F, Hayes TG. Male breast cancer: a review of the literature. Eur J Cancer 1998;34(9):1341-7
   PubMed Web of Science ®Google Scholar
• Thomas DB. Breast cancer in men. Epidemiol Rev 1993;15(1):220-31
   PubMed Web of Science ®Google Scholar
• English JC 3rd, Middleton C, Patterson JW, Slingluff CL. Cancer of the male breast. Int J Dermatol 2000;39(12):881-6
   PubMed Web of Science ®Google Scholar
• Nirmul D, Pegoraro RJ, Jialal I, et al. The sex hormone profile of male patients with breast cancer. Br J Cancer 1983;48(3):423-7
   PubMed Web of Science ®Google Scholar
• Srinivasan G, Srinivasan U, Greiver P. Male breast carcinoma following estrogen therapy: report of a case. J Ky Med Assoc 1979;77(1):9-10,48
   Google Scholar
• Schlappack OK, Braun O, Maier U. Report of two cases of male breast cancer after prolonged estrogen treatment for prostatic carcinoma. Cancer Detect Prev 1986;9(3-4):319-22
   PubMedGoogle Scholar
• Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-karim FW. Breast cancer in a male-to-female transsexual. A case report. JAMA 1988;259(15):2278-80
   PubMed Web of Science ®Google Scholar
• Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995;82(3):341
   PubMed Web of Science ®Google Scholar
• Symmers WS. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 1968;2(5597):83-5
   PubMed Web of Science ®Google Scholar
• Medras M, Filus A, Jozkow P, et al. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat 2006;96(3):263-5
   PubMed Web of Science ®Google Scholar
• Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004;96(4):338-9
   PubMed Web of Science ®Google Scholar
• Hirose Y, Sasa M, Bando Y, et al. Bilateral male breast cancer with male potential hypogonadism. World J Surg Oncol 2007;5:60
   PubMedGoogle Scholar
• Jackson AW, Muldal S, Ockey CH, O'Connor PJ. Carcinoma of male breast in association with the Klinefelter syndrome. Br Med J 1965;1(5429):223-5
   PubMed Web of Science ®Google Scholar
• Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand [A] 1973;81(3):352-8
   PubMedGoogle Scholar
• Hultborn R, Hanson C, Kopf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997;17(6D):4293-7
   PubMed Web of Science ®Google Scholar
• Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet 1971;8(4):460-1
   PubMed Web of Science ®Google Scholar
• Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367(9510):595-604
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Tryggvadottir L, Olafsdottir GH, et al. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995;346(8974):544-5
   PubMed Web of Science ®Google Scholar
• Couch FJ, Farid LM, Deshano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13(1):123-5
   PubMed Web of Science ®Google Scholar
• Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998;58(7):1367-71
   PubMed Web of Science ®Google Scholar
• Syrjakoski K, Kuukasjarvi T, Waltering K, et al. BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 2004;6(5):541-5
   PubMed Web of Science ®Google Scholar
• Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60(2):313-9
   PubMed Web of Science ®Google Scholar
• Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6):1480-90
   PubMed Web of Science ®Google Scholar
• Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4(1):R2
   PubMedGoogle Scholar
• Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001;38(3):159-64
   PubMed Web of Science ®Google Scholar
• Meijers-Heijboer H, van den Ouweland A, et al. CHEK2-breast cancer consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31(1):55-9
   PubMed Web of Science ®Google Scholar
• Wasielewski M, den Bakker MA, van den Ouweland A, et al. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009;116(2):397-400. [Epub 31 Aug 2008]
   PubMed Web of Science ®Google Scholar
• Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP. CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004;108(3):475-6
   PubMed Web of Science ®Google Scholar
• Ohayon T, Gal I, Baruch RG, et al. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004;108(3):479-80
   PubMed Web of Science ®Google Scholar
• Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38(3):476-9
   PubMed Web of Science ®Google Scholar
• Griffin JF, Wilson JD. Disorders of the testes. In: Isselbacher KJ, editor, Harrison's Principles of Internal Medicine. 13th edition. New York: Mc-Graw-Hill, Inc.; 1994. p. 2006-17
   Google Scholar
• Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, editor, Williams Textbook of Endocrinology. 9th edition. Philadelphia: W.B.Saunders Company; 1998. p. 517-664
   Google Scholar
• Bhasin S, Jameson JL. Disorders of the testes and male reproductive system In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al, editors, Harrison's Principles of Internal Medicine. 17th edition. The McGraw-Hill Companies, Inc.; 2008
   Google Scholar
• Simpson ER. Role of aromatase in sex steroid action. J Mol Endocrinol 2000;25(2):149-56
   PubMed Web of Science ®Google Scholar
• Sasano H, Ozaki M. Aromatase expression and its localization in human breast cancer. J Steroid Biochem Mol Biol 1997;61(3-6):293-8
   PubMed Web of Science ®Google Scholar
• Dakin Hachè K, Gray S, Barnes PJ, et al. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 2007;105(2):169-75
   PubMed Web of Science ®Google Scholar
• Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology (Williston Park) 2001;15(8):965-72; discussion 72, 77-9
   PubMed Web of Science ®Google Scholar
• Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer 1998;83(9):1947-55
   PubMed Web of Science ®Google Scholar
• Ruff SJ, Bauer JE, Keenan EJ, et al. Hormone receptors in male breast carcinoma. J Surg Oncol 1981;18(1):55-9
   PubMed Web of Science ®Google Scholar
• Nomura Y, Kondo H, Yamagata J, Takenaka K. Detection of the estrogen receptor and response to endocrine therapy in male breast cancer patients. Gann 1977;68(3):333-6
   PubMedGoogle Scholar
• Everson RB, Lippman ME, Thompson EB, et al. Clinical correlations of steroid receptors and male breast cancer. Cancer Res 1980;40(4):991-7
   PubMed Web of Science ®Google Scholar
• Gupta N, Cohen JL, Rosenbaum C, Raam S. Estrogen receptors in male breast cancer. Cancer 1980;46(8):1781-4
   PubMed Web of Science ®Google Scholar
• Mercer RJ, Bryan RM, Bennett RC. Hormone receptors in male breast cancer. Aust N Z J Surg 1984;54(3):215-8
   PubMedGoogle Scholar
• Morimoto T, Komaki K, Yamakawa T, et al. Cancer of the male breast. J Surg Oncol 1990;44(3):180-4
   PubMed Web of Science ®Google Scholar
• Davis SL, Barse F, Meoli FG. Male breast carcinoma: clinical experience in a suburban community. J Am Osteopath Assoc 1992;92(8):1005-6, 13-6
   PubMedGoogle Scholar
• Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995;31A(12):1960-4
   PubMed Web of Science ®Google Scholar
• Williams WL Jr, Powers M, Wagman LD. Cancer of the male breast: a review. J Natl Med Assoc 1996;88(7):439-43
   PubMed Web of Science ®Google Scholar
• Munoz de Toro MM, Maffini MV, Kass L, Luque EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 1998;67(4):333-9
   PubMed Web of Science ®Google Scholar
• Pich A, Margaria E, Chiusa L, et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 1999;79(5-6):959-64
   PubMed Web of Science ®Google Scholar
• Meijer-van Gelder ME, Look MP, Bolt-de Vries J, et al. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001;68(3):249-60
   PubMed Web of Science ®Google Scholar
• Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 1996;32A(10):1686-92
   PubMed Web of Science ®Google Scholar
• Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998;83(3):498-509
   PubMed Web of Science ®Google Scholar
• Calandra RS, Charreau EH, Royer de Giaroli M, Baldi A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res 1984;142:97-108
   PubMedGoogle Scholar
• Kidwai N, Gong Y, Sun X, et al. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004;6(1):R18-23
   PubMed Web of Science ®Google Scholar
• Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer 2004;101(1):51-7
   PubMed Web of Science ®Google Scholar
• Anderson WF. The descriptive epidemiology of male versus female breast cancer, using age-period-cohort (APC) models. 2008 ASCO Breast Cancer Symposium:abstract 93
   Google Scholar
• Anderson WF, Chu KC, Chatterjee N, Brinton LA. Male breast cancer (MBC) in the SEER database. Proc Annu Meet Am Soc Clin Oncol 2001;20:A1691
   Google Scholar
• Romain S, Laine Bidron C, Martin PM, Magdelenat H. Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group. Eur J Cancer 1995;31A(3):411-7
   PubMedGoogle Scholar
• El-Tamer M, Hibshoosh H, Troxel A. Estrogen and progesterone receptors: comparison in age-matched men and women with breast cancer. Program and abstracts of the 23rd Annual San Antonio Breast Cancer Symposium; December 6-9, 2000. Breast Cancer Res Treat 2000;64:128
   Google Scholar
• Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182(4):389-92
   PubMed Web of Science ®Google Scholar
• Barlund M, Kuukasjarvi T, Syrjakoski K, et al. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 2004;111(6):968-71
   PubMed Web of Science ®Google Scholar
• Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137(8):678-87
   PubMed Web of Science ®Google Scholar
• Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996;77(3):490-8
   PubMed Web of Science ®Google Scholar
• Shpitz B, Bomstein Y, Sternberg A, et al. Angiogenesis, p53 and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol 2000;75(4):252-7
   PubMed Web of Science ®Google Scholar
• Bines J, Goss B, Hussong J, et al. C-erb-B2 and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997;16:A558
   Google Scholar
• Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84(3):215-23
   PubMed Web of Science ®Google Scholar
• Avisar E, McParland E, Dicostanzo D, Axelrod D. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer 2006;7(4):331-5
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Schulten HJ, Golas MM, et al. Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 2006;118(10):2455-60
   PubMed Web of Science ®Google Scholar
• Andre S, Pinto AE, Laranjeira C, et al. Male and female breast cancer–differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 2007;74(6):323-7
   PubMed Web of Science ®Google Scholar
• Fassan MBR, Palazzo JP, Lloyd J, et al. MicroRNA expression profiling of male breast cancer. 2008 ASCO Breast Cancer Symposium:abstract 125
   Google Scholar
• Shak S, Palmer G, Baehner FL, et al. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol 2009;27(15s):abstract 549
   Google Scholar
• Breast Cancer. NCCN practice guidelines in oncology 2009. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
   Google Scholar
• Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25(3):235-7
   PubMed Web of Science ®Google Scholar
• PDQ®. Male breast cancer treatment. National cancer institute 2009. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/malebreast/Patient
   Google Scholar
• Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast 2007;16(6):653-6
   PubMed Web of Science ®Google Scholar
• Herrmann JB. The effect of hormonal imbalance on advanced carcinoma of the male breast. Ann Surg 1951;133(2):191-9
   PubMed Web of Science ®Google Scholar
• Hultborn R, Friberg S, Hultborn KA, et al. Male breast carcinoma. II. A study of the total material reported to the Swedish Cancer Registry 1958 – 1967 with respect to treatment, prognostic factors and survival. Acta Oncol 1987;26(5):327-41
   PubMed Web of Science ®Google Scholar
• Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. Cancer 1981;47(9):2185-9
   PubMed Web of Science ®Google Scholar
• Neifeld JP, Meyskens F, Tormey DC, Javadpour N. The role of orchiectomy in the management of advanced male breast cancer. Cancer 1976;37(2):992-5
   PubMed Web of Science ®Google Scholar
• Treves N. The treatment of cancer, especially inoperable cancer of the male breast, by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids); an analysis of 42 patients. Cancer 1959;12(4):820-32
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983;143(2):237-40
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Belanger A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 1990;13(5):275-8
   PubMed Web of Science ®Google Scholar
• Borgen PI. Male breast cancer. Semin Surg Oncol 1991;7(5):314-9
   PubMedGoogle Scholar
• Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988;62(3):474-8
   PubMed Web of Science ®Google Scholar
• Lopez M, Barduagni A. Cyproterone acetate in advanced male breast cancer. Cancer 1982;49(1):9-11
   PubMed Web of Science ®Google Scholar
• Vorobiof DA, Falkson G. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987;59(4):688-9
   PubMed Web of Science ®Google Scholar
• Kennedy BJ, Kiang DT. Hypophysectomy in the treatment of advanced cancer of the male breast. Cancer 1972;29(6):1606-12
   PubMed Web of Science ®Google Scholar
• Lopez M, Di Lauro L, Lazzaro B, Papaldo P. Hormonal treatment of disseminated male breast cancer. Oncology 1985;42(6):345-9
   PubMed Web of Science ®Google Scholar
• Harris AL, Dowsett M, Stuart-Harris R, Smith IE. Role of aminoglutethimide in male breast cancer. Br J Cancer 1986;54(4):657-60
   PubMed Web of Science ®Google Scholar
• Feldman LD. Ketoconazole for male metastatic breast cancer. Ann Intern Med 1986;104(1):123-4
   PubMedGoogle Scholar
• Li MC, Janelli DE, Kelly EJ, et al. Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy. Cancer 1970;25(3):678-81
   PubMed Web of Science ®Google Scholar
• Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992;117(9):771-7
   PubMed Web of Science ®Google Scholar
• Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 1984;53(6):1344-6
   PubMed Web of Science ®Google Scholar
• Ribeiro GG. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer 1976;33(4):465-7
   PubMed Web of Science ®Google Scholar
• Pannuti F, Martoni A, Busutti L, et al. High-dose medroxyprogesterone acetate in advanced male breast cancer. Cancer Treat Rep 1982;66(9):1763-5
   PubMedGoogle Scholar
• Mitsuyasu R, Bonomi P, Anderson K, Fischer W Jr. Response to megestrol in male breast carcinoma. Arch Intern Med 1981;141(6):809-10
   PubMedGoogle Scholar
• Becher R, Hoffken K, Pape H, Schmidt CG. Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med 1981;305(3):169-70
   PubMedGoogle Scholar
• Abele R, Alberto P. Tamoxifen before orchiectomy for breast cancer in men. N Engl J Med 1981;305(18):1091-2
   PubMed Web of Science ®Google Scholar
• Patterson JS, Battersby LA, Bach BK. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 1980;64(6-7):801-4
   PubMedGoogle Scholar
• Comet B, Cutuli B, Penault-Llorca F, et al. Cancer du sein chez l'homme: revue de la littérature. Bull Cancer 2009;96(2):181-9
   PubMed Web of Science ®Google Scholar
• Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am 1990;70(5):1165-77
   PubMed Web of Science ®Google Scholar
• Dimitrov NV, Colucci P, Nagpal S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. Oncologist 2007;12(7):798-807
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Distefano A, Legha SS, et al. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep 1979;63(4):539-41
   PubMedGoogle Scholar
• Cantwell BM, Tong D, Minton M, et al. Tamoxifen and male breast cancer. Lancet 1978;2(8089):582-3
   PubMed Web of Science ®Google Scholar
• Aisner J, Ross DD, Wiernik PH. Tamoxifen in advanced male breast cancer. Arch Intern Med 1979;139(4):480-1
   PubMedGoogle Scholar
• Hilliard DA, Wilbur DW, Camacho ES. Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: a case report. J Surg Oncol 1984;25(1):42-3
   PubMed Web of Science ®Google Scholar
• Tateishi M, Toda T, Minamisono Y, et al. A 94 year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation. J Surg Oncol 1992;51(1):71-3
   PubMed Web of Science ®Google Scholar
• van Rijswijk RE, van Oostenbrugge RJ, Twijnstra A. A case of brain metastases from male breast cancer responding to tamoxifen. Eur J Cancer 1997;33(13):2282-3
   PubMed Web of Science ®Google Scholar
• Kanoh T, Iino Y, Horiguchi J, et al. A case report of advanced male breast cancer with an objective response to tamoxifen treatment. Breast Cancer 2000;7(3):256-60
   PubMedGoogle Scholar
• Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65(2):252-4
   PubMed Web of Science ®Google Scholar
• Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74(1):74-7
   PubMed Web of Science ®Google Scholar
• Visram H, Dent SF. Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol 2009;27(suppl):abstract e11613
   Google Scholar
• Takei H, Iino Y, Horiguchi J, et al. Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case. Surg Today 2001;31(2):149-51
   PubMed Web of Science ®Google Scholar
• Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007;101(1):123
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-67
   PubMed Web of Science ®Google Scholar
• Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18(22):3748-57
   PubMed Web of Science ®Google Scholar
• Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2
   PubMed Web of Science ®Google Scholar
• Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007;9(3):192-4
   PubMed Web of Science ®Google Scholar
• Pant K, Dutta U. Understanding and management of male breast cancer: a critical review. Med Oncol 2008;25(3):294-8
   PubMed Web of Science ®Google Scholar
• Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86(3-5):225-30
   PubMed Web of Science ®Google Scholar
• Brueggemeier R, Hackett J, Diaz-Cruz E. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26(3):331-45
   PubMed Web of Science ®Google Scholar
• Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74(8):1286-91
   PubMed Web of Science ®Google Scholar
• Lonning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat 1998;49(Suppl 1):S53-7; discussion S73-7
   PubMed Web of Science ®Google Scholar
• Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85(7):2370-7
   PubMed Web of Science ®Google Scholar
• Nordman IC, Dalley DN. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment? Breast J 2008;14(6):562-9
   PubMed Web of Science ®Google Scholar
• Nahleh ZA. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 2006;32(2):101-5
   PubMed Web of Science ®Google Scholar
• Ellinwood WE, Hess DL, Roselli CE, et al. Inhibition of aromatization stimulates luteinizing hormone and testosterone secretion in adult male rhesus monkeys. J Clin Endocrinol Metab 1984;59(6):1088-96
   PubMed Web of Science ®Google Scholar
• Shetty G, Krishnamurthy H, Krishnamurthy HN, et al. Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata). Steroids 1998;63(7-8):414-20
   PubMed Web of Science ®Google Scholar
• Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of ‘Arimidex’ (anastrozole; ZD1033)–a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996;58(4):439-45
   PubMed Web of Science ®Google Scholar
• Turner KJ, Morley M, Atanassova N, et al. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 2000;164(2):225-38
   PubMed Web of Science ®Google Scholar
• Knoche AJ, Michaud LB, Buzdar AU. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: MD Anderson Cancer Center experience. Breast J 1999;5(3):176-81
   PubMedGoogle Scholar
• Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005;90(1):26-30
   PubMed Web of Science ®Google Scholar
• Italiano A, Largillier R, Marcy PY, et al. Rémission complète par létrozole chez un homme traité pour un cancer du sein métastatique. Rev Med Interne 2004;25(4):323-4
   PubMed Web of Science ®Google Scholar
• Soon Wong N, Seong Ooi W, Pritchard K. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. J Clin Oncol 2007;25(24):3787
   PubMedGoogle Scholar
• Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24(21):e42-3
   PubMedGoogle Scholar
• Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: Biological and clinical implications. J Clin Oncol 2009;27(15s):abstract 1130
   Google Scholar
• Stewart PM. Aging and fountain-of-youth hormones. N Engl J Med 2006;355(16):1724-6
   PubMed Web of Science ®Google Scholar
• Horn Y, Roof B. Male breast cancer: two cases with objective regressions from calusterone (7 alpha, 17 beta-dimethyltestosterone) after failure of orchiectomy. Oncology 1976;33(4):188-91
   PubMed Web of Science ®Google Scholar
• Yap HY, Tashima CK, Blumenschein GR, et al. Chemotherapy for advanced male breast cancer. JAMA 1980;243(17):1739-41
   PubMed Web of Science ®Google Scholar
• Rivera E, Holmes FA, Frye D, et al. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 2000;89(11):2195-201
   PubMed Web of Science ®Google Scholar
• Alexandre J, Bleuzen P, Bonneterre J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18(3):562-73
   PubMed Web of Science ®Google Scholar
• Lopez M, Di Lauro L, Papaldo P, Lazzaro B. Chemotherapy in metastatic male breast cancer. Oncology 1985;42(4):205-9
   PubMed Web of Science ®Google Scholar
• Tranum BL, McDonald B, Thigpen T, et al. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 1982;49(5):835-9
   PubMed Web of Science ®Google Scholar
• Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999;10(5):553-60
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12(2):123-8
   PubMed Web of Science ®Google Scholar
• Tormey DC, Gelman R, Band PR, et al. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1982;50(7):1235-44
   PubMed Web of Science ®Google Scholar
• Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19(6):1707-15
   PubMed Web of Science ®Google Scholar
• Sandler B, Carman C, Perry RR. Cancer of the male breast. Am Surg 1994;60(11):816-20
   PubMed Web of Science ®Google Scholar
• Rudlowski C, Rath W, Becker AJ, et al. Trastuzumab and breast cancer. N Engl J Med 2001;345(13):997-8
   PubMed Web of Science ®Google Scholar
• Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer 2009;16(2):136-40
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A. Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 2007;16(3):323-5
   PubMed Web of Science ®Google Scholar
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451-67
   PubMed Web of Science ®Google Scholar
• Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret hospital during 40 years: 1955 – 1996. Cancer 1999;85(3):629-39
   PubMed Web of Science ®Google Scholar
• Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104(11):2359-64
   PubMed Web of Science ®Google Scholar
• Vinod SK, Pendlebury SC. Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol 1999;43(1):69-72
   PubMedGoogle Scholar
• Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998;24(6):548-52
   PubMed Web of Science ®Google Scholar
• Margaria E, Chiusa L, Ferrari L, et al. Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep 2000;7(5):1035-9
   PubMed Web of Science ®Google Scholar
• Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989;64(8):1583-5
   PubMed Web of Science ®Google Scholar
• Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987;10(1):55-60
   PubMed Web of Science ®Google Scholar
• Walshe JM, Berman AW, Vatas U, et al. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 2007;103(2):177-83
   PubMed Web of Science ®Google Scholar
• Tamoxifen and chemotherapy US. National Institutes of Health, PDQ adult treatment editorial board 2008. Available from: http://www.nci.nih.gov/cancertopics/pdq/treatment/breast/healthprofessional/allpages#Section_556
   Google Scholar
• Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337(14):956-62
   PubMed Web of Science ®Google Scholar
• Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337(14):949-55
   PubMed Web of Science ®Google Scholar
• Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6(7):1107-17
   PubMed Web of Science ®Google Scholar
• Heller KS, Rosen PP, Schottenfeld D, et al. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978;188(1):60-5
   PubMed Web of Science ®Google Scholar
• Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990;76(6):555-8
   PubMed Web of Science ®Google Scholar
• Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994;30A(7):930-5
   PubMed Web of Science ®Google Scholar
• Rudan I, Rudan N, Basic N, et al. Differences between male and female breast cancer. III. Prognostic features. Acta Med Croatica 1997;51(3):135-41
   PubMedGoogle Scholar
• Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007;109(8):1471-7
   PubMed Web of Science ®Google Scholar
• Langlands AO, Maclean N, Kerr GR. Carcinoma of the male breast: report of a series of 88 cases. Clin Radiol 1976;27(1):21-5
   PubMed Web of Science ®Google Scholar
• Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 1984;2(8):903-9
   PubMed Web of Science ®Google Scholar
• Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993;71(1):154-61
   PubMed Web of Science ®Google Scholar
• Willsher PC, Leach IH, Ellis IO, et al. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997;173(3):185-8
   PubMed Web of Science ®Google Scholar
• Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997;4(5):385-8
   PubMed Web of Science ®Google Scholar
• Carmalt HL, Mann LJ, Kennedy CW, et al. Carcinoma of the male breast: a review and recommendations for management. Aust N Z J Surg 1998;68(10):712-5
   PubMedGoogle Scholar
• Vetto J, Jun SY, Paduch D, et al. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999;177(5):379-83
   PubMed Web of Science ®Google Scholar
• Herman K, Lobaziewicz W, Skotnicki P, et al. Male breast cancer. Does the prognosis differ compared to female? Neoplasma 2000;47(3):191-5
   Google Scholar
• van Geel AN, van Slooten EA, Mavrunac M, Hart AA. A retrospective study of male breast cancer in Holland. Br J Surg 1985;72(9):724-7
   PubMed Web of Science ®Google Scholar
• Park S, Kim JH, Koo J, et al. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008;49(6):978-86
   PubMed Web of Science ®Google Scholar
• Botan RD, Alvares MN, Hassan A. Male breast cancer: Prognostic factors evaluation in a 35-year service. J Clin Oncol 2009;27(suppl):abstract e11618
   Google Scholar
• Andre S, Fonseca I, Pinto AE, et al. Male breast cancer–a reappraisal of clinical and biologic indicators of prognosis. Acta Oncol 2001;40(4):472-8
   PubMed Web of Science ®Google Scholar
• Rudan I, Rudan N, Basic N, et al. Differences between male and female breast cancer. II. Clinicopathologic features. Acta Med Croatica 1997;51(3):129-33
   PubMedGoogle Scholar
• Clark JL, Nguyen PL, Jaszcz WB, et al. Prognostic variables in male breast cancer. Am Surg 2000;66(5):502-11
   PubMed Web of Science ®Google Scholar
• Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005;10(7):471-9
   PubMed Web of Science ®Google Scholar
• SEER. Surveillance, epidemiology, and end results program. 1988 – 2001. Available from: http://seer.cancer.gov/publications/survival/
   Google Scholar
• Lanitis S, Rice AJ, Vaughan A, et al. Diagnosis and management of male breast cancer. World J Surg 2008;32(11):2471-6
   PubMed Web of Science ®Google Scholar
• Schaub NP, Maloney N, Schneider H, et al. Changes in male breast cancer over a 30-year period. Am Surg 2008;74(8):707-11; discussion 11-2
   PubMed Web of Science ®Google Scholar
• SEER Cancer statistics review, 1975 – 2005; Breast. Available from: http://seer.cancer.gov/csr/1975_2006/index.html
   Google Scholar
• Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26(22):3785-90
   PubMed Web of Science ®Google Scholar